Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTAI NASDAQ:CRBP NASDAQ:MOLN NASDAQ:TNYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTAIBioXcel Therapeutics$1.41+0.7%$1.19$1.01▼$8.08$43.23M0.3614,481 shs345,946 shsCRBPCorbus Pharmaceuticals$9.38+4.5%$9.30$6.72▼$20.56$166.38M2.57488,169 shs585,935 shsMOLNMolecular Partners$3.87-2.3%$4.03$3.41▼$5.36$159.88M1.077,513 shs903 shsTNYATenaya Therapeutics$0.74+0.6%$0.77$0.53▼$2.35$159.47M2.822.64 million shs990,370 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTAIBioXcel Therapeutics+0.71%+11.90%+20.51%+15.57%-22.10%CRBPCorbus Pharmaceuticals+4.45%+10.87%+18.58%-6.01%+35.94%MOLNMolecular Partners-2.27%+0.78%-5.03%-1.65%+2.11%TNYATenaya Therapeutics+0.57%+1.80%-14.95%+8.53%+20.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTAIBioXcel Therapeutics$1.41+0.7%$1.19$1.01▼$8.08$43.23M0.3614,481 shs345,946 shsCRBPCorbus Pharmaceuticals$9.38+4.5%$9.30$6.72▼$20.56$166.38M2.57488,169 shs585,935 shsMOLNMolecular Partners$3.87-2.3%$4.03$3.41▼$5.36$159.88M1.077,513 shs903 shsTNYATenaya Therapeutics$0.74+0.6%$0.77$0.53▼$2.35$159.47M2.822.64 million shs990,370 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTAIBioXcel Therapeutics+0.71%+11.90%+20.51%+15.57%-22.10%CRBPCorbus Pharmaceuticals+4.45%+10.87%+18.58%-6.01%+35.94%MOLNMolecular Partners-2.27%+0.78%-5.03%-1.65%+2.11%TNYATenaya Therapeutics+0.57%+1.80%-14.95%+8.53%+20.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTAIBioXcel Therapeutics 2.25Hold$11.00680.14% UpsideCRBPCorbus Pharmaceuticals 2.75Moderate Buy$40.67333.55% UpsideMOLNMolecular Partners 2.25Hold$8.38116.41% UpsideTNYATenaya Therapeutics 2.86Moderate Buy$4.00441.20% UpsideCurrent Analyst Ratings BreakdownLatest BTAI, CRBP, TNYA, and MOLN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2026CRBPCorbus Pharmaceuticals MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$44.00 ➝ $34.006/17/2026CRBPCorbus Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$54.00 ➝ $52.005/27/2026CRBPCorbus Pharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$38.00 ➝ $30.005/26/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/26/2026CRBPCorbus Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.005/22/2026CRBPCorbus Pharmaceuticals MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$40.00 ➝ $44.005/13/2026CRBPCorbus Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$57.00 ➝ $54.005/13/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.005/12/2026CRBPCorbus Pharmaceuticals Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$36.00 ➝ $33.004/29/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.004/22/2026MOLNMolecular Partners HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.00(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTAIBioXcel Therapeutics$640K68.03N/AN/A($4.37) per share-0.32CRBPCorbus PharmaceuticalsN/AN/AN/AN/A$8.40 per shareN/AMOLNMolecular Partners$5.65M27.66N/AN/A$2.40 per share1.61TNYATenaya TherapeuticsN/AN/AN/AN/A$0.57 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTAIBioXcel Therapeutics-$69.90M-$5.75N/AN/AN/A-11,078.53%N/A-201.53%8/11/2026 (Estimated)CRBPCorbus Pharmaceuticals-$78.54M-$5.82N/AN/AN/AN/A-70.89%-61.78%8/11/2026 (Estimated)MOLNMolecular Partners-$74.41M-$1.94N/AN/AN/AN/A-66.62%-54.85%8/24/2026 (Estimated)TNYATenaya Therapeutics-$90.60M-$0.47N/AN/AN/AN/A-80.56%-65.21%8/5/2026 (Estimated)Latest BTAI, CRBP, TNYA, and MOLN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BTAIBioXcel Therapeutics-$0.5325-$0.54-$0.0075-$0.54$0.38 million$0.21 million5/12/2026Q1 2026CRBPCorbus Pharmaceuticals-$1.26-$1.23+$0.03-$1.23N/AN/A5/11/2026Q1 2026MOLNMolecular Partners-$0.4340-$0.45-$0.0160-$0.44N/AN/A5/6/2026Q1 2026TNYATenaya Therapeutics-$0.09-$0.09N/A-$0.09$7.50 million$0.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBTAIBioXcel TherapeuticsN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/ATNYATenaya TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTAIBioXcel TherapeuticsN/A0.620.61CRBPCorbus PharmaceuticalsN/A7.927.92MOLNMolecular PartnersN/A9.439.43TNYATenaya TherapeuticsN/A5.755.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTAIBioXcel Therapeutics30.68%CRBPCorbus Pharmaceuticals64.64%MOLNMolecular Partners26.55%TNYATenaya Therapeutics90.54%Insider OwnershipCompanyInsider OwnershipBTAIBioXcel Therapeutics3.70%CRBPCorbus Pharmaceuticals3.50%MOLNMolecular Partners5.93%TNYATenaya Therapeutics2.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTAIBioXcel Therapeutics9030.88 million29.74 millionNo DataCRBPCorbus Pharmaceuticals4018.53 million17.88 millionOptionableMOLNMolecular Partners18040.38 million37.98 millionNot OptionableTNYATenaya Therapeutics110217.00 million211.51 millionOptionableBTAI, CRBP, TNYA, and MOLN HeadlinesRecent News About These CompaniesTenaya Names Eric Hyllengren as CFOJune 29 at 8:29 PM | marketwatch.comTenaya Therapeutics Appoints Eric Hyllengren as Chief Financial OfficerJune 29 at 8:30 AM | globenewswire.comTenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks TranscriptJune 5, 2026 | seekingalpha.comAnalysts Are Bullish on Top Healthcare Stocks: Ligand Pharma (LGND), Tenaya Therapeutics (TNYA)June 5, 2026 | theglobeandmail.comTenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac ...June 4, 2026 | finance.yahoo.comTenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in SymptomsJune 3, 2026 | globenewswire.comTenaya Therapeutics to Report Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 Gene Therapy for HCM on June 3, 2026June 2, 2026 | quiverquant.comQTenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026June 2, 2026 | globenewswire.comTenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026May 29, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Knight Therapeutics (OtherKHTRF) and TScan Therapeutics (TCRX)May 25, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: ImmunityBio (IBRX) and Tenaya Therapeutics (TNYA)May 20, 2026 | theglobeandmail.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 9.02%May 18, 2026 | aaii.comAPositive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with ...May 15, 2026 | markets.businessinsider.comTenaya Therapeutics' gene therapy data highlights early heart rhythm improvementsMay 15, 2026 | msn.comTenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVC TranscriptMay 15, 2026 | seekingalpha.comTenaya Therapeutics Reports Significant Reductions in Premature Ventricular Contractions in Interim Results from TN-401 Gene Therapy Clinical TrialMay 15, 2026 | quiverquant.comQPositive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVCMay 15, 2026 | globenewswire.comTenaya Therapeutics (TNYA) Is Up 26.6% After TN-401 Data Buzz and Narrower Losses Has The Bull Case Changed?May 12, 2026 | finance.yahoo.comAnalysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Context Therapeutics (CNTX)May 11, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Tenaya Therapeutics (TNYA)May 7, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBTAI, CRBP, TNYA, and MOLN Company DescriptionsBioXcel Therapeutics NASDAQ:BTAI$1.41 +0.01 (+0.71%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$1.38 -0.03 (-2.20%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Corbus Pharmaceuticals NASDAQ:CRBP$9.38 +0.40 (+4.45%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$8.91 -0.47 (-4.97%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Molecular Partners NASDAQ:MOLN$3.87 -0.09 (-2.27%) Closing price 06/30/2026 03:46 PM EasternExtended Trading$3.84 -0.03 (-0.88%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Tenaya Therapeutics NASDAQ:TNYA$0.74 +0.00 (+0.57%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$0.72 -0.02 (-2.85%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
